These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. A Systematic Review and Meta-analyses of Longitudinal Studies on Drug Treatments for Gaucher Disease. Leonart LP; Fachi MM; Böger B; Silva MRD; Szpak R; Lombardi NF; Pedroso MLA; Pontarolo R Ann Pharmacother; 2023 Mar; 57(3):267-282. PubMed ID: 35815393 [TBL] [Abstract][Full Text] [Related]
45. Long-term efficacy and safety results of taliglucerase alfa through 5years in adult treatment-naïve patients with Gaucher disease. Zimran A; Durán G; Giraldo P; Rosenbaum H; Giona F; Petakov M; Terreros Muñoz E; Solorio-Meza SE; Cooper PA; Varughese S; Alon S; Chertkoff R Blood Cells Mol Dis; 2019 Sep; 78():14-21. PubMed ID: 27499018 [TBL] [Abstract][Full Text] [Related]
46. Taliglucerase alfa: an enzyme replacement therapy using plant cell expression technology. Grabowski GA; Golembo M; Shaaltiel Y Mol Genet Metab; 2014 May; 112(1):1-8. PubMed ID: 24630271 [TBL] [Abstract][Full Text] [Related]
47. A Phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase. Pastores GM; Petakov M; Giraldo P; Rosenbaum H; Szer J; Deegan PB; Amato DJ; Mengel E; Tan ES; Chertkoff R; Brill-Almon E; Zimran A Blood Cells Mol Dis; 2014 Dec; 53(4):253-60. PubMed ID: 24950666 [TBL] [Abstract][Full Text] [Related]
48. Reported outcomes of 453 pregnancies in patients with Gaucher disease: An analysis from the Gaucher outcome survey. Lau H; Belmatoug N; Deegan P; Goker-Alpan O; Schwartz IVD; Shankar SP; Panahloo Z; Zimran A Blood Cells Mol Dis; 2018 Feb; 68():226-231. PubMed ID: 27839985 [TBL] [Abstract][Full Text] [Related]
49. Rapid intravenous infusion of velaglucerase-alfa in adults with type 1 Gaucher disease. Zimran A; Revel-Vilk S; Becker-Cohen M; Chicco G; Arbel N; Rolfs A; Szer J Am J Hematol; 2018 Sep; 93(9):E246-E248. PubMed ID: 29989200 [No Abstract] [Full Text] [Related]
50. Velaglucerase alfa as a therapeutic option for Gaucher disease. Pastores GM Expert Rev Endocrinol Metab; 2011 Jan; 6(1):13-20. PubMed ID: 30764031 [TBL] [Abstract][Full Text] [Related]
51. Long-term efficacy and safety results of taliglucerase alfa up to 36 months in adult treatment-naïve patients with Gaucher disease. Zimran A; Durán G; Mehta A; Giraldo P; Rosenbaum H; Giona F; Amato DJ; Petakov M; Muñoz ET; Solorio-Meza SE; Cooper PA; Varughese S; Chertkoff R; Brill-Almon E Am J Hematol; 2016 Jul; 91(7):656-60. PubMed ID: 27174694 [TBL] [Abstract][Full Text] [Related]
52. Significant and continuous improvement in bone mineral density among type 1 Gaucher disease patients treated with velaglucerase alfa: 69-month experience, including dose reduction. Elstein D; Foldes AJ; Zahrieh D; Cohn GM; Djordjevic M; Brutaru C; Zimran A Blood Cells Mol Dis; 2011 Jun; 47(1):56-61. PubMed ID: 21536468 [TBL] [Abstract][Full Text] [Related]
53. Rapid velaglucerase alfa infusion for Gaucher disease: 5-year data. Becker-Cohen M; Szer J; Arbel N; Frydman D; Dinur T; Istaiti M; Revel-Vilk S; Zimran A Intern Med J; 2022 Sep; 52(9):1645-1646. PubMed ID: 36100564 [No Abstract] [Full Text] [Related]
54. Intravenous enzyme replacement therapy: better in home or hospital? Milligan A; Hughes D; Goodwin S; Richfield L; Mehta A Br J Nurs; 2006 Mar 23-Apr 12; 15(6):330-3. PubMed ID: 16628169 [TBL] [Abstract][Full Text] [Related]
55. Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease. Zimran A; Brill-Almon E; Chertkoff R; Petakov M; Blanco-Favela F; Muñoz ET; Solorio-Meza SE; Amato D; Duran G; Giona F; Heitner R; Rosenbaum H; Giraldo P; Mehta A; Park G; Phillips M; Elstein D; Altarescu G; Szleifer M; Hashmueli S; Aviezer D Blood; 2011 Nov; 118(22):5767-73. PubMed ID: 21900191 [TBL] [Abstract][Full Text] [Related]
56. [Enzyme replacement therapy in adult patients with type I Gaucher disease]. Ponomarev RV; Lukina EA Ter Arkh; 2019 Jul; 91(7):127-131. PubMed ID: 32598746 [TBL] [Abstract][Full Text] [Related]
57. Relationship Between Glucocerebrosidase Activity and Clinical Response to Enzyme Replacement Therapy in Patients With Gaucher Disease Type I. Gras-Colomer E; Martínez-Gómez MA; Climente-Martí M; Fernandez-Zarzoso M; Almela-Tejedo M; Giner-Galvañ V; Marcos-Rodríguez JA; Rodríguez-Fernández A; Torralba-Cabeza MÁ; Merino-Sanjuan M Basic Clin Pharmacol Toxicol; 2018 Jul; 123(1):65-71. PubMed ID: 29418074 [TBL] [Abstract][Full Text] [Related]
58. Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients. Tsuboi K; Yamamoto H BMC Pharmacol Toxicol; 2017 Jun; 18(1):43. PubMed ID: 28592315 [TBL] [Abstract][Full Text] [Related]
59. Cholangiocarcinoma occurring in a patient with type 1 Gaucher disease treated with velaglucerase alfa enzyme replacement therapy: First case report. Holubar J; Bres V; Costes-Martineau V; Pers YM Blood Cells Mol Dis; 2018 Feb; 68():112-114. PubMed ID: 28559130 [No Abstract] [Full Text] [Related]
60. A multicenter, open-label, phase III study of Abcertin in Gaucher disease. Lee BH; Abdalla AF; Choi JH; Beshlawy AE; Kim GH; Heo SH; Megahed AMH; Elsayed MAL; Barakat TEM; Eid KMAE; El-Tagui MH; Mahmoud MMH; Fateen E; Park JY; Yoo HW Medicine (Baltimore); 2017 Nov; 96(45):e8492. PubMed ID: 29137040 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]